ERBB2 and Hypercholesterolemia: Concerning the cardiovascular risk factors (CVRFs), most women with CT had at least five previously reported CVRFs [16] before anti-HER-2 therapy (tobacco consumption, diabetes mellitus II, hypertension, obesity, and hypercholesterolemia), with odds ratios of 13.6, 1.3, 0.9, 2.1, and 1.4, respectively.